Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Teresa Casals
Observed names:
Teresa Casals Galobart,
Teresa Casals-Galobart
Institution:
Vall d'Hebron Institute of Oncology
Observed institutions:
Royal Marsden NHS Foundation Trust,
Institute of Cancer Research,
Cancer Research UK,
Vall d'Hebron Hospital Universitari,
Vall d'Hebron Institute of Oncology
ORCID:
0009-0000-9173-6387
Observed ORCID:
0009-0000-9173-6387
OpenAlex ID:
A5120534135
MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy
2017
·
Mounia Beloueche-Babari
, Slawomir Wantuch
, et al.
·
Cancer Research
·
180
Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells
2019
·
Teresa Delgado-Goñi
, Teresa Casals Galobart
, et al.
·
British Journal of Cancer
·
44
PDF
Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer
2019
·
Alejandro Athie
, Sara Arce-Gallego
, et al.
·
Current Oncology Reports
·
22
Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging
2017
·
Anant Shah
, Teresa Delgado-Goni
, et al.
·
Scientific Reports
·
15
PDF
Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
·
Molecular Cancer Therapeutics
·
7
Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer
2025
·
Sara Arce-Gallego
, Victor Esquefa
, et al.
·
npj Precision Oncology
·
4
PDF
Abstract B018: Impact of 13q.14 loss in prostate cancer progression and sensitivity to targeted agents
2026
·
Victor Esquefa
, Pablo Cresta Morgado
, et al.
·
Cancer Research
Supplementary Figure 2 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
Table S1 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
Supplementary Figure 4 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
PDF
Table S10 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
Supplementary Figure 3 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
PDF
Table S4 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
Table S3 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
Supplementary Figure 5 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
PDF
Supplementary Figure 1 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
PDF
Supplementary Figure 6 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
PDF
Table S6 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
Table S5 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
Table S8 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
Table S9 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
Table S2 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
Table S7 from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
Data from Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
2025
·
Julian Brandariz
, Lara de Llobet
, et al.
Abstract 4108: Longitudinal diffusion-weighted MRI assessment of NRAS mutant melanoma response to dual RAF-MEK inhibition reveals differences associated with collagen deposition
2018
·
Teresa Delgado-Goni
, Slawomir Wantuch
, et al.
·
Cancer Research
Show more works
View as search
Works count:
25
Citation count:
272
H-index:
5
I10-index:
4
Year
Topic
Type